Trial Outcomes & Findings for Acamprosate in Youth With Fragile X Syndrome (NCT NCT01300923)
NCT ID: NCT01300923
Last Updated: 2019-07-30
Results Overview
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
COMPLETED
PHASE2
14 participants
Week 10
2019-07-30
Participant Flow
The psychophysiological measures proved non-feasible as subjects could not tolerate the procedures. The paradigms were tried on two subjects in the Autism Spectrum Disorder arm; however, the data that was collected was not usable. Subsequently, neurobiological characterization was halted.
Participant milestones
| Measure |
Acamprosate
The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg.
Acamprosate
|
Autism Spectrum Disorder (ADS)
This baseline comparison group will participated in only and biomarker portion of subject characterization.
|
|---|---|---|
|
Overall Study
STARTED
|
12
|
2
|
|
Overall Study
COMPLETED
|
12
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
2
|
Reasons for withdrawal
| Measure |
Acamprosate
The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg.
Acamprosate
|
Autism Spectrum Disorder (ADS)
This baseline comparison group will participated in only and biomarker portion of subject characterization.
|
|---|---|---|
|
Overall Study
Physician Decision
|
0
|
2
|
Baseline Characteristics
Acamprosate in Youth With Fragile X Syndrome
Baseline characteristics by cohort
| Measure |
Acamprosate Treatment Group
n=12 Participants
Twelve subjects received open-label acamprosate, mean final of 1,054 mg/day (range: 666-1,998 mg/day)
|
|---|---|
|
Age, Categorical
<=18 years
|
12 Participants
n=99 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=99 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
|
Age, Continuous
|
11.9 years
n=99 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=99 Participants
|
|
Region of Enrollment
United States
|
12 participants
n=99 Participants
|
|
Aberrant Behavior Checklist
ABC Irritability
|
9.9 units on a scale
STANDARD_DEVIATION 7.8 • n=99 Participants
|
|
Aberrant Behavior Checklist
ABC Social Withdrawal
|
8.8 units on a scale
STANDARD_DEVIATION 5.8 • n=99 Participants
|
|
Aberrant Behavior Checklist
ABC Stereotypy
|
6.8 units on a scale
STANDARD_DEVIATION 6.8 • n=99 Participants
|
|
Aberrant Behavior Checklist
ABC Hyperactivity
|
16.8 units on a scale
STANDARD_DEVIATION 9.1 • n=99 Participants
|
|
Aberrant Behavior Checklist
ABC Inappropriate Speech
|
5.2 units on a scale
STANDARD_DEVIATION 3.5 • n=99 Participants
|
|
Aberrant Behavior Checklist
ABC Social Avoidance
|
3.3 units on a scale
STANDARD_DEVIATION 2.6 • n=99 Participants
|
|
Clinical Global Impression -Severity
|
4.25 units on a scale
STANDARD_DEVIATION 0.45 • n=99 Participants
|
|
Children's Yale-Brown Obsessive Compulsive Scale Modified for PDD
|
11.1 units on a scale
STANDARD_DEVIATION 2.6 • n=99 Participants
|
|
Social Responsiveness Scale
|
91.3 units on a scale
STANDARD_DEVIATION 27.4 • n=99 Participants
|
|
ADHD Rating Scale 4th Edition
|
23.6 units on a scale
STANDARD_DEVIATION 10.6 • n=99 Participants
|
|
Peabody Picture Vocabulary Test
|
85.2 units on a scale
STANDARD_DEVIATION 32.0 • n=99 Participants
|
|
Vineland Adaptive Behavior Scales-II (VABS-II) Communication Domain
Communication Domain
|
63.4 units on a scale
STANDARD_DEVIATION 10.0 • n=99 Participants
|
|
Vineland Adaptive Behavior Scales-II (VABS-II) Communication Domain
Expressive Communication Domain
|
69.8 units on a scale
STANDARD_DEVIATION 23.0 • n=99 Participants
|
|
Brain-derived neurotropic factor
|
790.4 pg/mL
STANDARD_DEVIATION 1.3050 • n=99 Participants
|
PRIMARY outcome
Timeframe: Week 10The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Outcome measures
| Measure |
Acamprosate Treatment Group
n=12 Participants
Twelve subjects received open-label acamprosate, mean final of 1,054 mg/day (range: 666-1,998 mg/day).
|
|---|---|
|
Clinical Global Impression- Severity Scale (CGI-S)
|
7.0 units on a scale
Standard Deviation 8.9
|
SECONDARY outcome
Timeframe: Week 10The Aberrant Behavior Checklist (ABC) is a 58-item rating scale used to assess maladaptive behaviors across five original subscales: Irritability (15 items from 0-45), Social Withdrawal (16 items from 0-48), Stereotypy (7 items from 0-21), Hyperactivity (16 items from 0-48), Inappropriate Speech (4 items from 0-12). Additionally, Social Avoidance, a newly developed four-item subscale (from 0-12) of the ABC that captures core social avoidance aspects of Fragile X Syndrome is reported. All items on the ABC are rated from 0 (not at all a problem) to 3 (the problem is severe in degree). Higher scores indicate greater maladaptive behaviors. Differences between Baseline and Week 10 are used as an indicator of change.
Outcome measures
| Measure |
Acamprosate Treatment Group
n=12 Participants
Twelve subjects received open-label acamprosate, mean final of 1,054 mg/day (range: 666-1,998 mg/day).
|
|---|---|
|
The Aberrant Behavior Checklist (ABC)
ABC Irritability
|
7.0 units on a scale
Standard Deviation 8.9
|
|
The Aberrant Behavior Checklist (ABC)
ABC Social Withdrawal
|
4.1 units on a scale
Standard Deviation 6.5
|
|
The Aberrant Behavior Checklist (ABC)
ABC Stereotypy
|
6.0 units on a scale
Standard Deviation 6.3
|
|
The Aberrant Behavior Checklist (ABC)
ABC Hyperactivity
|
11.0 units on a scale
Standard Deviation 8.6
|
|
The Aberrant Behavior Checklist (ABC)
ABC Inappropriate Speech
|
4.8 units on a scale
Standard Deviation 3.4
|
|
The Aberrant Behavior Checklist (ABC)
ABC Social Avoidance
|
1.6 units on a scale
Standard Deviation 2.7
|
SECONDARY outcome
Timeframe: Week 10The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The score of each individual item is summed to create a total raw score. A total scores results are as follows: 0-62: Within normal limits 63-79: Mild range of impairment 80-108: Moderate range of impairment 109-149: Severe range of impairment
Outcome measures
| Measure |
Acamprosate Treatment Group
n=12 Participants
Twelve subjects received open-label acamprosate, mean final of 1,054 mg/day (range: 666-1,998 mg/day).
|
|---|---|
|
Social Responsiveness Scale
|
76.4 units on a scale
Standard Deviation 26.8
|
SECONDARY outcome
Timeframe: Week 10The Children's Yale-Brown Obsessive Compulsive Scales-Modified (CY-BOCS) is a 5-item, semi-structured clinician rating scale modified designed to rate the current severity of repetitive behavior in children and adolescents with PDD. Once the current repetitive behaviors are identified, they are separately rated on 5 items: Time Spent, Interference, Distress, Resistance, and Control. Each of these items is scored on a 5-point scale form 0 (least symptomatic) to 4 (most symptomatic). The CY-BOCS yields a Total Score from 0 to 20 and is sensitive to change.
Outcome measures
| Measure |
Acamprosate Treatment Group
n=12 Participants
Twelve subjects received open-label acamprosate, mean final of 1,054 mg/day (range: 666-1,998 mg/day).
|
|---|---|
|
Children's Yale-Brown Obsessive Compulsive Scale Modified for PDD
|
9.8 units on a scale
Standard Deviation 4.1
|
SECONDARY outcome
Timeframe: Week 10The ADHD Rating Scale is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder. The ADHD Rating Scale-IV is completed by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. The total score can range from 0 to 54, with a higher score indicating greater severity.
Outcome measures
| Measure |
Acamprosate Treatment Group
n=12 Participants
Twelve subjects received open-label acamprosate, mean final of 1,054 mg/day (range: 666-1,998 mg/day).
|
|---|---|
|
ADHD Rating Scale 4th Edition
|
16.7 units on a scale
Standard Deviation 8.0
|
SECONDARY outcome
Timeframe: Week 10The VABS-II is a semi-structured interview designed to assess adaptive functioning in communication, daily living, socialization and motor skills. Recognizing that language is a major area of impairment in the study population, the Communication Domain (99 Items from 0-198), in particular the Expressive Subdomain (54 Items from 0-108) are of interest in this study. Items arranged in a developmental sequence are rated on a 3-point scale. Each item is scored from 0 (never performs the behavior) to 3 (usually performs the behavior independently). Higher scores indicate higher adaptive functioning. Differences between Baseline and Week 10 are used as an indicator of change.
Outcome measures
| Measure |
Acamprosate Treatment Group
n=12 Participants
Twelve subjects received open-label acamprosate, mean final of 1,054 mg/day (range: 666-1,998 mg/day).
|
|---|---|
|
Vineland Adaptive Behavior Scales-II (VABS-II) Communication Domain
Communication Domain
|
66.6 units on a scale
Standard Deviation 11.2
|
|
Vineland Adaptive Behavior Scales-II (VABS-II) Communication Domain
Expressive Communication
|
78.9 units on a scale
Standard Deviation 21.2
|
SECONDARY outcome
Timeframe: Week 10The Peabody Picture Vocabulary Test is one of the most commonly used assessment tests that measure verbal ability in standard American English vocabulary. This test has been nationally standardized using examinees from various age groups, from children to adults. Thus, the raw scores are equated to mental age, using the norms obtained from standardization. The total standard scores range from 40 (worse receptive vocabulary) to 160 (better receptive vocabulary). The scores can also be converted to percentile rank.
Outcome measures
| Measure |
Acamprosate Treatment Group
n=12 Participants
Twelve subjects received open-label acamprosate, mean final of 1,054 mg/day (range: 666-1,998 mg/day).
|
|---|---|
|
Peabody Picture Vocabulary
|
83.3 units on a scale
Standard Deviation 32.0
|
SECONDARY outcome
Timeframe: Screen and Week 10BDNF is a protein that supports the survival of existing neurons and growth and differentiation of new neurons and synapses.
Outcome measures
| Measure |
Acamprosate Treatment Group
n=10 Participants
Twelve subjects received open-label acamprosate, mean final of 1,054 mg/day (range: 666-1,998 mg/day).
|
|---|---|
|
Brain-derived Neurotrophic Factor (BDNF)
|
1,007.6 pg/mL
Standard Deviation 1,493.2
|
Adverse Events
Acamprosate
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Acamprosate
n=12 participants at risk
The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg.
|
|---|---|
|
Psychiatric disorders
Irritability
|
33.3%
4/12 • Number of events 4 • Ten Weeks
|
|
Psychiatric disorders
Increased repetitive behavior
|
16.7%
2/12 • Number of events 2 • Ten Weeks
|
|
Gastrointestinal disorders
Diarrhea
|
8.3%
1/12 • Number of events 1 • Ten Weeks
|
|
Gastrointestinal disorders
mild constipation
|
8.3%
1/12 • Number of events 1 • Ten Weeks
|
|
Psychiatric disorders
Increased anxiety
|
8.3%
1/12 • Number of events 1 • Ten Weeks
|
|
Psychiatric disorders
Insomnia
|
8.3%
1/12 • Number of events 1 • Ten Weeks
|
|
Psychiatric disorders
Nightmares
|
8.3%
1/12 • Number of events 1 • Ten Weeks
|
|
Infections and infestations
Rhinitis
|
8.3%
1/12 • Number of events 1 • Ten Weeks
|
|
Renal and urinary disorders
Urinary Urgency
|
8.3%
1/12 • Number of events 1 • Ten Weeks
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place